![David Anderson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Anderson
Directeur/Membre du Conseil chez Halsa Pharmaceuticals, Inc.
Postes actifs de David Anderson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Halsa Pharmaceuticals, Inc. | Directeur/Membre du Conseil | - | - |
Historique de carrière de David Anderson
Anciens postes connus de David Anderson
Sociétés | Poste | Début | Fin |
---|---|---|---|
MithraGen, Inc.
![]() MithraGen, Inc. Pharmaceuticals: MajorHealth Technology MithraGen, Inc. develops immunotherapies for the treatment and prevention of cancer and infectious diseases. The company was founded in 2000 and is headquartered in Houston, TX. | Président | 01/01/2009 | 01/01/2009 |
President | 01/01/2001 | - | |
PLx Pharma, Inc. /Old/
![]() PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | 24/08/2011 | - |
Président | - | 24/08/2011 | |
Tanox, Inc.
![]() Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Directeur/Membre du Conseil | 01/01/1987 | - |
Directeur des opérations | 01/01/1987 | - | |
Nanospectra Biosciences, Inc.
![]() Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Président | - | - |
Formation de David Anderson
University of Houston | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Chairman | 3 |
Director/Board Member | 3 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 5 |
---|---|
Nanospectra Biosciences, Inc.
![]() Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Health Technology |
PLx Pharma, Inc. /Old/
![]() PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
Tanox, Inc.
![]() Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
MithraGen, Inc.
![]() MithraGen, Inc. Pharmaceuticals: MajorHealth Technology MithraGen, Inc. develops immunotherapies for the treatment and prevention of cancer and infectious diseases. The company was founded in 2000 and is headquartered in Houston, TX. | Health Technology |
Halsa Pharmaceuticals, Inc. |
- Bourse
- Insiders
- David Anderson
- Expérience